Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.69) for the quarter, down from their prior forecast of ($0.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($2.01) EPS and FY2026 earnings at ($1.82) EPS.

Several other research firms have also recently weighed in on ZNTL. Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.81 on Monday. The company’s fifty day moving average is $2.04 and its two-hundred day moving average is $2.85. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $16.27. The firm has a market capitalization of $129.98 million, a price-to-earnings ratio of -0.73 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Integral Health Asset Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $3,182,000. Verition Fund Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after buying an additional 951,500 shares during the period. Almitas Capital LLC raised its position in shares of Zentalis Pharmaceuticals by 69.3% during the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock worth $4,929,000 after acquiring an additional 665,968 shares during the last quarter. Boxer Capital Management LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $1,364,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock valued at $2,605,000 after acquiring an additional 370,511 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.